Tech Company Financing Transactions
Latus Bio Funding Round
Latus Bio closed a $54 million Series A financing round on 5/3/2024. Backers included 8VC, DCVC Bio and Children's Hospital Colorado.
Transaction Overview
Company Name
Announced On
5/3/2024
Transaction Type
Venture Equity
Amount
$54,000,000
Round
Series A
Proceeds Purpose
The company intends to use the funds to accelerate the development of its candidates for CLN2 disease, with first-in-human dosing planned in late 2025.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Philadelphia, PA Undisclosed
USA
Philadelphia, PA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Latus develops innovative gene therapy candidates that use precision delivery with the goal of improving the lives of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Ghoroghchian
Chief Scientific Officer
Jang-Ho Cha
VP - Bus. Development
John Connelly
VP - Operations
Kerry Eischen
Browse more venture capital transactions:
Prev: 5/3/2024: AISAP venture capital transaction
Next: 5/3/2024: Allozymes venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC transactions reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs